PharmacoEconomics

1997 - 2025

Current editor(s): Timothy Wrightson and Christopher I. Carswell

From Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

Access Statistics for this journal.
Is something missing from the series or not right? See the RePEc data check for the archive and series.

Volume 39, issue 12, 2021

Health-Economic Analyses of Diagnostics: Guidance on Design and Reporting pp. 1355-1363

Simon Pol, Paula Rojas Garcia, Fernando Antoñanzas Villar, Maarten J. Postma and Antoinette D. I. Asselt

Why the Gap in Evaluating the Social Constructs and the Value of Medicines? pp. 1365-1372

Jacquelyn McRae and Eberechukwu Onukwugha

A Practical Guide to Modeling and Conducting a Cost-Effectiveness Analysis of Companion Biomarker Tests for Targeted Therapies Using R: Tutorial Paper pp. 1373-1381

Mikyung Kelly Seo and Mark Strong

Conceptualising ‘Benefits Beyond Health’ in the Context of the Quality-Adjusted Life-Year: A Critical Interpretive Synthesis pp. 1383-1395

Lidia Engel, Stirling Bryan and David G. T. Whitehurst

Filgotinib for Moderate to Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 1397-1410

Sabine E. Grimm, Ben Wijnen, Rob Riemsma, Debra Fayter, Nigel Armstrong, Charlotte Ahmadu, Lloyd Brandts, Kate Misso, John R. Kirwan, Jos Kleijnen and Manuela A. Joore

Economic Analyses of Respiratory Tract Infection Diagnostics: A Systematic Review pp. 1411-1427

Simon van der Pol, Paula Rojas Garcia, Maarten J. Postma, Fernando Antoñanzas Villar and Antoinette D. I. Asselt

Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer pp. 1429-1442

Martijn J. H. G. Simons, Valesca P. Retèl, Bram L. T. Ramaekers, Rogier Butter, Joanne M. Mankor, Marthe S. Paats, Joachim G. J. V. Aerts, Zakile A. Mfumbilwa, Paul Roepman, Veerle M. H. Coupé, Carin A. Uyl- de Groot, Wim H. van Harten and Manuela A. Joore

What Aspects of Illness Influence Public Preferences for Healthcare Priority Setting? A Discrete Choice Experiment in the UK pp. 1443-1454

Liz Morrell, James Buchanan, Sian Rees, Richard W. Barker and Sarah Wordsworth

Assessing Technologies for COVID-19: What are the Challenges for Health Technology Assessment Agencies? Findings From a Survey and Roundtable Workshop pp. 1455-1463

Jamie Elvidge and Dalia Dawoud

Volume 39, issue 11, 2021

Principles of Economic Evaluation in a Pandemic Setting: An Expert Panel Discussion on Value Assessment During the Coronavirus Disease 2019 Pandemic pp. 1201-1208

Yumi Asukai, Andrew Briggs, Louis P. Garrison, Benjamin P. Geisler, Peter J. Neumann and Daniel A. Ollendorf

The Challenges of Measuring Informal Care Time: A Review of the Literature pp. 1209-1223

Sean Urwin, Yiu-Shing Lau, Gunn Grande and Matt Sutton

The Use of Cost-Effectiveness Analysis in Sickle Cell Disease: A Critical Review of the Literature pp. 1225-1241

Boshen Jiao, Anirban Basu, Joshua Roth, M. Bender, Ilsa Rovira, Traci Clemons, Dalyna Quach, Scott Ramsey and Beth Devine

How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment pp. 1243-1269

Michael Schlander, Karla Hernandez-Villafuerte, Chih-Yuan Cheng, Jorge Mestre-Ferrandiz and Michael Baumann

A Systematic Review of Economic and Quality-of-Life Research in Carcinoid Syndrome pp. 1271-1297

I-Wen Pan, Daniel M. Halperin, Bumyang Kim, James C. Yao and Ya-Chen Tina Shih

EQ-5D-Y Population Norms for Japanese Children and Adolescents pp. 1299-1308

Takeru Shiroiwa and Takashi Fukuda

Cost Effectiveness of Triplet Selinexor-Bortezomib-Dexamethasone (XVd) in Previously Treated Multiple Myeloma (MM) Based on Results from the Phase III BOSTON Trial pp. 1309-1325

Michael Dolph, Gabriel Tremblay and Hoyee Leong

Cost Effectiveness of Screening for Hepatitis C Virus in Iraq in the Era of Simplified Testing and Treatment pp. 1327-1341

Bassem Asker, Raghad Jawad, Rabah Asreah, Haydar Jamal, Ahmed Jassem, Muslim Abdelkareem Inaya, Hiwa Abou Baker, Sam Kozma, Eid Mansour, Bryony McNamara, Ryan Miller, Oliver Darlington, Phil McEwan, Daniel M. Sugrue and Haidar Jarallah

Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective pp. 1343-1354

Adnan Alsumali, Laurence M Djatche, Andrew Briggs, Rongzhe Liu, Ibrahim Diakite, Dipen Patel, Yufei Wang and Dominik Lautsch

Volume 39, issue 10, 2021

Contextual Considerations and Recommendations for Estimating the Value of Alzheimer’s Disease Therapies pp. 1101-1107

T. Joseph Mattingly, R. Brett McQueen and Pei-Jung Lin

A Review of Utility Measurement Methods Used in Pharmacoeconomic Submissions to HIRA in South Korea: Methodological Consistency and Areas for Improvement pp. 1109-1121

Jihyung Hong and Eun-Young Bae

Lack of Cost-Effectiveness of Preoperative Erythropoiesis-Stimulating Agents and/or Iron Therapy in Anaemic, Elective Surgery Patients: A Systematic Review and Updated Analysis pp. 1123-1139

Bert Avau, Hans Van Remoortel, Jorien Laermans, Geertruida Bekkering, Dean Fergusson, Jørgen Georgsen, Paola Maria Manzini, Yves Ozier, Emmy De Buck, Veerle Compernolle and Philippe Vandekerckhove

Patient Utilities in Health States Based on Hoehn and Yahr and Off-Time in Parkinson’s Disease: A Swedish Register-Based Study in 1823 Observations pp. 1141-1149

Jenny M. Norlin, Klas Kellerborg and Per Odin

Valuing SF-6Dv2 in Australia Using an International Protocol pp. 1151-1162

Brendan Mulhern, Richard Norman and John Brazier

Lifetime Costs for Treated Follicular Lymphoma Patients in the US pp. 1163-1183

Caitlin Eichten, Qiufei Ma, Thomas E. Delea, May Hagiwara, Roberto Ramos, Şerban R. Iorga, Jie Zhang and Richard T. Maziarz

State of the ART? Two New Tools for Risk Communication in Health Technology Assessments pp. 1185-1196

Sabine E. Grimm, Xavier Pouwels, Bram L. T. Ramaekers, Ben Wijnen, Thomas Otten, Janneke Grutters and Manuela A. Joore

Deterministic Sensitivity Analysis Under Ignorance pp. 1197-1198

Afschin Gandjour

Comment on “Deterministic Sensitivity Analysis Under Ignorance” pp. 1199-1199

Rick A. Vreman, Joost W Geenen, Saskia Knies, Aukje K. Mantel-Teeuwisse, Hubert G. M. Leufkens and Wim G. Goettsch

Volume 39, issue 9, 2021

Characterization of the Pharmaceutical Risk-Sharing Arrangement Process in Catalonia pp. 973-982

Anna Reyes-Travé, Laura Guarga-Solé, Marta Roig-Izquierdo, Enrique Alonso-Pérez, Ana Clopés-Estela and Joaquín Delgadillo-Duarte

Aspects and Challenges of Resource Use Measurement in Health Economics: Towards a Comprehensive Measurement Framework pp. 983-993

Luca M. M. Janssen, Ruben M. W. A. Drost, Aggie T. G. Paulus, Kirsty Garfield, William Hollingworth, Sian Noble, Joanna C. Thorn, Irina Pokhilenko and Silvia M. A. A. Evers

Economic Evidence on Potentially Curative Gene Therapy Products: A Systematic Literature Review pp. 995-1019

Joseph Khoa Ho, Kennedy Borle, Nick Dragojlovic, Manrubby Dhillon, Vanessa Kitchin, Nicola Kopac, Colin Ross and Larry D. Lynd

Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel pp. 1021-1044

Karen M. Facey, Jaime Espin, Emma Kent, Angèl Link, Elena Nicod, Aisling O’Leary, Entela Xoxi, Inneke Vijver, Anna Zaremba, Tatyana Benisheva, Andrius Vagoras and Sheela Upadhyaya

Cost Effectiveness of Ribociclib in Combination with Fulvestrant for the Treatment of Postmenopausal Women with HR+/HER2− Advanced Breast Cancer Who Have Received No or Only One Prior Line of Endocrine Therapy: A Canadian Healthcare Perspective pp. 1045-1058

Daniel Stellato, Marroon E. Thabane, Jinhee Park, David Chandiwana and Thomas E. Delea

A Net Benefit Approach for the Optimal Allocation of a COVID-19 Vaccine pp. 1059-1073

Erin Kirwin, Ellen Rafferty, Kate Harback, Jeff Round and Christopher McCabe

Towards Transparency in the Selection of Published Health Utility Inputs in Cost-Utility Analyses: The Health Utility Application Tool (HAT) pp. 1075-1084

Michael J. Zoratti, Kelvin K. W. Chan, Don Husereau, Murray Krahn, Mitchell Levine, Lehana Thabane and Feng Xie

Estimation of an EORTC QLU-C10 Value Set for Spain Using a Discrete Choice Experiment pp. 1085-1098

Aureliano Paolo Finch, Eva Gamper, Richard Norman, Rosalie Viney, Bernhard Holzner, Madeleine King and Georg Kemmler

Correction to: Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study pp. 1099-1099

Becky Pennington, Abualbishr Alshreef, Laura Flight, Andrew Metry, Edith Poku, Philip Hykin, Sobha Sivaprasad, A. Toby Prevost, Joana C. Vasconcelos, Caroline Murphy, Joanna Kelly, Yit Yang, Andrew Lotery, Michael Williams and John Brazier

Volume 39, issue 8, 2021

Estimation of Transition Probabilities for State-Transition Models: A Review of NICE Appraisals pp. 869-878

Tushar Srivastava, Nicholas R. Latimer and Paul Tappenden

Jointly Modelling Economics and Epidemiology to Support Public Policy Decisions for the COVID-19 Response: A Review of UK Studies pp. 879-887

Ana Duarte, Simon Walker, Andrew Metry, Ruth Wong, Jasmina Panovska-Griffiths and Mark Sculpher

Do Costs in the Education Sector Matter? A Systematic Literature Review of the Economic Impact of Psychosocial Problems on the Education Sector pp. 889-900

Irina Pokhilenko, Luca M. M. Janssen, Silvia M. A. A. Evers, Ruben M. W. A. Drost, Lena Schnitzler and Aggie T. G. Paulus

Utility Values Associated with Atypical Hemolytic Uremic Syndrome-Related Attributes: A Discrete Choice Experiment in Five Countries pp. 901-912

Kate Williams, Daniel Aggio, Peter Chen, Katerina Anokhina, Andrew J. Lloyd and Yan Wang

Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study pp. 913-927

Becky Pennington, Abualbishr Alshreef, Laura Flight, Andrew Metry, Edith Poku, Philip Hykin, Sobha Sivaprasad, A. Toby Prevost, Joana C. Vasconcelos, Caroline Murphy, Joanna Kelly, Yit Yang, Andrew Lotery, Michael Williams and John Brazier

A Comparison of the SF-6Dv2 and SF-6D UK Utility Values in a Mixed Patient and Healthy Population pp. 929-940

Emily McDool, Clara Mukuria and John Brazier

The Cost-Effectiveness of Lorlatinib Versus Chemotherapy as a Second- or Third-Line Treatment in Anaplastic Lymphoma Kinase (ALK)-Positive Non-small-cell Lung Cancer in Sweden pp. 941-952

Fredrik O. L. Nilsson, Sandra T. Asanin, Elizabeth T. Masters, Laura Iadeluca, Chrissy Almond, Miranda Cooper and Sarah Smith

Circulating Tumour DNA as a Potential Cost-Effective Biomarker to Reduce Adjuvant Chemotherapy Overtreatment in Stage II Colorectal Cancer pp. 953-964

Yat Hang To, Koen Degeling, Suzanne Kosmider, Rachel Wong, Margaret Lee, Catherine Dunn, Grace Gard, Azim Jalali, Vanessa Wong, Maarten IJzerman, Peter Gibbs and Jeanne Tie

Comment on Keeney et al.’s “Delphi Analysis of Relevant Comparators in a Cost-Effectiveness Model of Prostate Cancer Screening” pp. 965-967

James F. O’Mahony

Response to Comment on Delphi Analysis of Relevant Comparators in a Cost-Effectiveness Model of Prostate Cancer Screening pp. 969-970

Edna Keeney, Howard Thom, Emma Turner, Richard M. Martin and Sabina Sanghera

Retraction Note to: The EQ-5D-5L Valuation Study in Egypt pp. 971-971

Sahar A. Shabasy, Maggie M. Abbassi, Aureliano Paolo Finch, Darrin Baines and Samar F. Farid

Volume 39, issue 7, 2021

Healthcare Funding Decisions and Real-World Benefits: Reducing Bias by Matching Untreated Patients pp. 741-756

Peter Ghijben, Dennis Petrie, Silva Zavarsek, Gang Chen and Emily Lancsar

Overview and Use of Tools for Selecting Modelling Techniques in Health Economic Studies pp. 757-770

Huajie Jin, Stewart Robinson, Wenru Shang, Evanthia Achilla, David Aceituno and Sarah Byford

Guidance for the Harmonisation and Improvement of Economic Evaluations of Personalised Medicine pp. 771-788

Heleen Vellekoop, Simone Huygens, Matthijs Versteegh, László Szilberhorn, Tamás Zelei, Balázs Nagy, Rositsa Koleva-Kolarova, Apostolos Tsiachristas, Sarah Wordsworth and Maureen Rutten- van Mölken

Economic Burden of Multiple Sclerosis in Low- and Middle‐Income Countries: A Systematic Review pp. 789-807

Jalal Dahham, Rana Rizk, Ingrid Kremer, Silvia M. A. A. Evers and Mickaël Hiligsmann

What are the Economic Costs to Society Attributable to Alcohol Use? A Systematic Review and Modelling Study pp. 809-822

Jakob Manthey, Syed Ahmed Hassan, Sinclair Carr, Carolin Kilian, Sören Kuitunen-Paul and Jürgen Rehm

Health Economists on Involving Patients in Modeling: Potential Benefits, Harms, and Variables of Interest pp. 823-833

Stephanie Harvard and Gregory R. Werker

Cost-of-Illness Progression Before and After Diagnosis of Multiple Sclerosis: A Nationwide Register-Based Cohort Study in Sweden of People Newly Diagnosed with Multiple Sclerosis and a Population-Based Matched Reference Group pp. 835-851

Chantelle Murley, Petter Tinghög, Kristina Alexanderson, Jan Hillert, Emilie Friberg and Korinna Karampampa

Cost Effectiveness of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Pre-/Perimenopausal, HR+ and HER2− Advanced Breast Cancer: A Canadian Healthcare Perspective pp. 853-867

Daniel Stellato, Marroon E. Thabane, David Chandiwana, Jinhee Park and Thomas E. Delea

Volume 39, issue 6, 2021

Introduction to the Special Issue of PharmacoEconomics on Major Depressive Disorders pp. 617-617

Paul E. Greenberg and Tammy Sisitsky

The Growing Burden of Major Depressive Disorders (MDD): Implications for Researchers and Policy Makers pp. 619-625

David Proudman, Paul Greenberg and Dave Nellesen

Overlap of Depressive Symptoms with Health-Related Quality-of-Life Measures pp. 627-630

Ron D. Hays and Peter M. Fayers

Putting Stakeholder Engagement at the Center of Health Economic Modeling for Health Technology Assessment in the United States pp. 631-638

Richard Z. Xie, Erica deFur Malik, Mark T. Linthicum and Jennifer L. Bright

Economic Burden of Treatment-Resistant Depression among Adults with Chronic Non-Cancer Pain Conditions and Major Depressive Disorder in the US pp. 639-651

Drishti Shah, Lindsay Allen, Wanhong Zheng, Suresh S. Madhavan, Wenhui Wei, Traci J. LeMasters and Usha Sambamoorthi

The Economic Burden of Adults with Major Depressive Disorder in the United States (2010 and 2018) pp. 653-665

Paul E. Greenberg, Andree-Anne Fournier, Tammy Sisitsky, Mark Simes, Richard Berman, Sarah H. Koenigsberg and Ronald C. Kessler

The Excess Costs of Depression and the Influence of Sociodemographic and Socioeconomic Factors: Results from the German Health Interview and Examination Survey for Adults (DEGS) pp. 667-680

Hannah König, Alexander Rommel, Julia Thom, Christian Schmidt, Hans-Helmut König, Christian Brettschneider and Alexander Konnopka

Investigating the Association Between Self-Reported Comorbid Anxiety and Depression and Health Service Use in Cancer Survivors pp. 681-690

Jackie Yim, Joanne Shaw, Rosalie Viney, Sheena Arora, Nicole Ezendam and Alison Pearce

The Increasing Economic Burden with Additional Steps of Pharmacotherapy in Major Depressive Disorder pp. 691-706

Alix Arnaud, Ellison Suthoff, Rita M. Tavares, Xuan Zhang and Aditi J. Ravindranath

Cluster Analysis of Care Pathways in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior in the USA pp. 707-720

Maryia Zhdanava, Jennifer Voelker, Dominic Pilon, Tom Cornwall, Laura Morrison, Maude Vermette-Laforme, Patrick Lefebvre, Abigail I. Nash, Kruti Joshi and Cheryl Neslusan

Real-World Treatment Costs and Care Utilization in Patients with Major Depressive Disorder With and Without Psychiatric Comorbidities in Specialist Mental Healthcare pp. 721-730

Kaying Kan, Joran Lokkerbol, Frederike Jörg, Ellen Visser, Robert A. Schoevers and Talitha L. Feenstra

Postnatal Major Depressive Disorder in Australia: Inequalities and Costs of Healthcare to Individuals, Governments and Insurers pp. 731-739

Emily J. Callander, Jenny Gamble and Debra K. Creedy

Volume 39, issue 5, 2021

Hispa-NICE: A Pipe Dream or a Realistic and Necessary Initiative? pp. 481-483

Fernando Antoñanzas

Direct Medical Costs, Productivity Loss Costs and Out-Of-Pocket Expenditures in Women with Breast Cancer in Latin America and the Caribbean: A Systematic Review pp. 485-502

Alfredo Palacios, Carlos Rojas-Roque, Lucas González, Ariel Bardach, Agustín Ciapponi, Claudia Peckaitis, Andres Pichon-Riviere and Federico Augustovski

Utility Decrements Associated with Adult Overweight and Obesity in Australia: A Systematic Review and Meta-Analysis pp. 503-519

Joseph Carrello, Alison Hayes, Anagha Killedar, Amy Huben, Louise A. Baur, Stavros Petrou and Thomas Lung

Valuation of SF-6Dv2 Health States in China Using Time Trade-off and Discrete-Choice Experiment with a Duration Dimension pp. 521-535

Jing Wu, Shitong Xie, Xiaoning He, Gang Chen, Gengliang Bai, Da Feng, Ming Hu, Jie Jiang, Xiaohui Wang, Hongyan Wu, Qunhong Wu and John E. Brazier

Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada pp. 537-548

Yong-Jin Kim, Mark Oremus, Helen H. Chen, Thomas McFarlane, Danielle Fearon and Susan Horton

RETRACTED ARTICLE: The EQ-5D-5L Valuation Study in Egypt pp. 549-561

Sahar A. Al Shabasy, Maggie M. Abbassi, Aureliano Paolo Finch, Darrin Baines and Samar F. Farid

Cost Effectiveness and Budget Impact of Siponimod Compared to Interferon Beta-1a in the Treatment of Adult Patients with Secondary Progressive Multiple Sclerosis with Active Disease in Switzerland pp. 563-577

Nadine Schur, Kapil Gudala, Umakanth Vudumula, Sreelatha Vadapalle, Arjun Bhadhuri, Alain Casanova, Nicholas Adlard and Matthias Schwenkglenks

Multiple Myeloma in Portugal: Burden of Disease and Cost of Illness pp. 579-587

Manuel Neves, Fernanda Trigo, Bergantim Rui, Cristina João, Paulo Lúcio, Neves Mariana, João Mendes, Hugo Pedrosa and Catarina Geraldes

Using a Modified Delphi Approach to Gain Consensus on Relevant Comparators in a Cost-Effectiveness Model: Application to Prostate Cancer Screening pp. 589-600

Edna Keeney, Howard Thom, Emma Turner, Richard M. Martin and Sabina Sanghera

Resource Utilization of Patients with Parkinson’s Disease in the Late Stages of the Disease in Germany: Data from the CLaSP Study pp. 601-615

Christopher Kruse, Sabrina Kretschmer, Anna Lipinski, Malte Verheyen, David Mengel, Monika Balzer-Geldsetzer, Stefan Lorenzl, Carmen Richinger, Christian Schmotz, Lars Tönges, Dirk Woitalla, Stephan Klebe, Anette Schrag and Richard Dodel

Volume 39, issue 4, 2021

Toward Modified Impact Inventory Tables to Facilitate Patient-Centered Value Assessment pp. 379-382

R. Brett McQueen and Julia F. Slejko

Methodological Challenges in the Economic Evaluation of a Gene Therapy for RPE65-Mediated Inherited Retinal Disease: The Value of Vision pp. 383-397

Simone A. Huygens, Matthijs M. Versteegh, Stefan Vegter, L. Jan Schouten and Tim A. Kanters

Global Economic Burden of Attention-Deficit/Hyperactivity Disorder: A Systematic Review pp. 399-420

Anindit Chhibber, Alexandre Hikiji Watanabe, Chayutthaphong Chaisai, Sajesh K. Veettil and Nathorn Chaiyakunapruk

The Cost-Effectiveness and Budget Impact of Ibalizumab-uiyk for Adults with Multidrug-Resistant HIV-1 Infection in the United States pp. 421-432

Anita J. Brogan, Sandra E. Talbird, Ashley E. Davis, Elizabeth M. La and Princy N. Kumar

Replication of Published Health Economic Obesity Models: Assessment of Facilitators, Hurdles and Reproduction Success pp. 433-446

Björn Schwander, Mark Nuijten, Silvia Evers and Mickaël Hiligsmann

Macrovascular Risk Equations Based on the CANVAS Program pp. 447-461

Michael Willis, Christian Asseburg, April Slee, Andreas Nilsson and Cheryl Neslusan

EQ-5D-Y Value Set for Slovenia pp. 463-471

Valentina Prevolnik Rupel and Marko Ogorevc

Comment on “Cost-Effectiveness of Cannabidiol Adjunct Therapy Versus Usual Care for the Treatment of Seizures in Lennox-Gastaut Syndrome” pp. 473-475

Kelly Hollenack and Jade Marshall

Authors’ Reply to Comment on “Cost-Effectiveness of Cannabidiol Adjunct Therapy Versus Usual Care for the Treatment of Seizures in Lennox-Gastaut Syndrome” pp. 477-478

Edward E. Neuberger, Josh J. Carlson and David L. Veenstra

The Continued Need for Transparent Evidence on the Cost Effectiveness of Drugs for Rare Diseases pp. 479-480

Jesse Elliott, George A. Wells and Doug Coyle

Volume 39, issue 3, 2021

Productivity-Adjusted Life-Years: A New Metric for Quantifying Disease Burden pp. 271-273

Zanfina Ademi, Ilana N. Ackerman, Ella Zomer and Danny Liew

Common Problems, Common Data Model Solutions: Evidence Generation for Health Technology Assessment pp. 275-285

Seamus Kent, Edward Burn, Dalia Dawoud, Pall Jonsson, Jens Torup Østby, Nigel Hughes, Peter Rijnbeek and Jacoline C. Bouvy

Assessment of the Effects of Active Immunisation against Respiratory Syncytial Virus (RSV) using Decision-Analytic Models: A Systematic Review with a Focus on Vaccination Strategies, Modelling Methods and Input Data pp. 287-315

Marina Treskova, Francisco Pozo-Martin, Stefan Scholz, Viktoria Schönfeld, Ole Wichmann and Thomas Harder

Budget Impact of Oral Semaglutide Intensification versus Sitagliptin among US Patients with Type 2 Diabetes Mellitus Uncontrolled with Metformin pp. 317-330

Elizabeth Wehler, Dominik Lautsch, Stacey Kowal, Glenn Davies, Andrew Briggs, Qianyi Li, Swapnil Rajpathak and Adnan Alsumali

Cost-Utility Analysis of a Dolutegravir-Based Versus Low-Dose Efavirenz-Based Regimen for the Initial Treatment of HIV-Infected Patients in Cameroon (NAMSAL ANRS 12313 Trial) pp. 331-343

Marwân-al-Qays Bousmah, Marie Libérée Nishimwe, Tamara Tovar-Sanchez, Martial Lantche Wandji, Mireille Mpoudi-Etame, Gwenaëlle Maradan, Pierrette Omgba Bassega, Marie Varloteaux, Alice Montoyo, Charles Kouanfack, Eric Delaporte and Sylvie Boyer

What Did Time Tell Us? A Comparison and Retrospective Validation of Different Survival Extrapolation Methods for Immuno-Oncologic Therapy in Advanced or Metastatic Renal Cell Carcinoma pp. 345-356

Sven L. Klijn, Elisabeth Fenwick, Sonja Kroep, Kasper Johannesen, Bill Malcolm, Murat Kurt, Christopher Kiff and John Borrill

Cost-Effectiveness of Erenumab for the Preventive Treatment of Migraine in Patients with Prior Treatment Failures in Sweden pp. 357-372

Ronan Mahon, Andrea Lang, Pamela Vo, Jasper Huels, Philip Cooney, Andriy Danyliv, Umakanth Vudumula, Sreelatha Vadapalle, Farooq Maniyar and Peter J. Goadsby

Early-Phase Clinical Trials and Reimbursement Submissions to the Pan-Canadian Oncology Drug Review pp. 373-377

Adam J. N. Raymakers, Kristina M. Jenei, Dean A. Regier, Michael M. Burgess and Stuart J. Peacock

Volume 39, issue 2, 2021

NICE’s Discounting Review: Clear Thinking on Rational Revision Meets Obstacle of Industrial Interests pp. 139-146

James F. O’Mahony, Mike Paulden and Chris McCabe

Modifying NICE’s Approach to Equity Weighting pp. 147-160

Mike Paulden and Christopher McCabe

Dealing with Bad Risk in Cost-Effectiveness Analysis: The Cost-Effectiveness Risk-Aversion Curve pp. 161-169

Pedram Sendi

Lenalidomide with Rituximab for Previously Treated Follicular Lymphoma and Marginal Zone Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 171-180

Willem J. A. Witlox, Sabine E. Grimm, Rob Riemsma, Nigel Armstrong, Steve Ryder, Steven Duffy, Vanesa Huertas Carrera, Pawel Posadzki, Gillian Worthy, Xavier G. L. V. Pouwels, Bram L. T. Ramaekers, Jos Kleijnen, Manuela A. Joore and Antoinette D. I. Asselt

An Updated Systematic Review of Cost-Effectiveness Analyses of Drugs for Osteoporosis pp. 181-209

Nannan Li, Dennis Cornelissen, Stuart Silverman, Daniel Pinto, Lei Si, Ingrid Kremer, Sandrine Bours, Robin de Bot, Annelies Boonen, Silvia Evers, Joop van den Bergh, Jean-Yves Reginster and Mickaël Hiligsmann

Health State Utilities of Patients with Heart Failure: A Systematic Literature Review pp. 211-229

Gian Luca Di Tanna, Michael Urbich, Heidi S. Wirtz, Barbara Potrata, Marieke Heisen, Craig Bennison, John Brazier and Gary Globe

The Budget Impact of Including Rucaparib on a US Payer Formulary for the Treatment of Patients with Metastatic Ovarian Cancer pp. 231-241

Katrine Wallace, Kelly Adamski, Ashwini Pai, Darya Rose and Anita Chawla

Predictors of Health Utility in Relapsing–Remitting and Secondary-Progressive Multiple Sclerosis: Implications for Future Economic Models of Disease-Modifying Therapies pp. 243-256

Luis Hernandez, Malinda O’Donnell and Maarten Postma

Comparing the Analysis and Results of a Modified Social Accounting Matrix Framework with Conventional Methods of Reporting Indirect Non-Medical Costs pp. 257-269

Baudouin Standaert, Christophe Sauboin, Quentin J. Leclerc and Mark P. Connolly

Volume 39, issue 1, 2021

The Application and Implications of Novel Deterministic Sensitivity Analysis Methods pp. 1-17

Rick A. Vreman, Joost W. Geenen, Saskia Knies, Aukje K. Mantel-Teeuwisse, Hubert G. M. Leufkens and Wim G. Goettsch

Probabilistic One-Way Sensitivity Analysis with Multiple Comparators: The Conditional Net Benefit Frontier pp. 19-24

Christopher McCabe, Giovanni Tramonti, Andrew Sutton, Peter Hall and Mike Paulden

Quantitative Evidence Synthesis Methods for the Assessment of the Effectiveness of Treatment Sequences for Clinical and Economic Decision Making: A Review and Taxonomy of Simplifying Assumptions pp. 25-61

Ruth A. Lewis, Dyfrig Hughes, Alex J. Sutton and Clare Wilkinson

Health Economic Evaluation Alongside Stepped Wedge Trials: A Methodological Systematic Review pp. 63-80

Thomas Lung, Lei Si, Richard Hooper and Gian Luca Di Tanna

Use of Productivity Loss/Gain in Cost-Effectiveness Analyses for Drugs: A Systematic Review pp. 81-97

Akira Yuasa, Naohiro Yonemoto, Michael LoPresti and Shunya Ikeda

The Relative Importance of Education and Criminal Justice Costs and Benefits in Economic Evaluations: A Best–Worst Scaling Experiment pp. 99-108

Irina Pokhilenko, Luca M. M. Janssen, Mickael Hiligsmann, Silvia M. A. A. Evers, Ruben M. W. A. Drost, Aggie T. G. Paulus and Leonarda G. M. Bremmers

Evaluating New Zealanders’ Values for Drug Coverage Decision Making: Trade-Offs between Treatments for Rare and Common Conditions pp. 109-119

Linda Yamoah, Nick Dragojlovic, Alesha Smith, Larry D. Lynd and Carlo A. Marra

Budget Impact Analysis of Gemtuzumab Ozogamicin for the Treatment of CD33-Positive Acute Myeloid Leukemia pp. 121-131

Carla Mamolo, Verna Welch, Roland B. Walter, Joseph C. Cappelleri, James Brockbank, Matthew Cawson, Chris Knight and Michele Wilson

Comment on “External Validation of the Core Obesity Model to Assess the Cost-Effectiveness of Weight Management Interventions” pp. 133-135

Bram L. T. Ramaekers, Ben Wijnen, Nigel Armstrong, Svenja Petersohn, Talitha Feenstra, Junfeng Wang and Manuela A. Joore

Authors’ reply to Comment on “External Validation of the Core Obesity Model to Assess the Cost-Effectiveness of Weight Management Interventions” pp. 137-138

Sandra Lopes, Pierre Johansen, Mark Lamotte, Phil McEwan, Anamaria-Vera Olivieri and Volker Foos